This is the first study to indicate the potent tumor immune promoting mechanisms of G-CSF and decreased neoplasm size after G-CSF blockade, suggesting that G-CSF is a potential therapeutic target for CRC. This evidence concerns the gene CSF3 and colorectal carcinoma.